Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Other Non Operating Income (2016 - 2025)

Coherus Oncology's Other Non Operating Income history spans 13 years, with the latest figure at -$5.2 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 72.55% year-over-year to -$5.2 million; the TTM value through Sep 2025 reached -$13.8 million, down 77.74%, while the annual FY2024 figure was -$12.6 million, 330.94% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$5.2 million at Coherus Oncology, down from $2.1 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $10.0 million in Q4 2022 and bottomed at -$19.0 million in Q4 2024.
  • The 5-year median for Other Non Operating Income is $124000.0 (2021), against an average of -$884450.0.
  • The largest annual shift saw Other Non Operating Income plummeted 22423.33% in 2022 before it surged 5300.0% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at -$385000.0 in 2021, then soared by 2708.83% to $10.0 million in 2022, then plummeted by 101.28% to -$129000.0 in 2023, then crashed by 14667.44% to -$19.0 million in 2024, then soared by 72.55% to -$5.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Other Non Operating Income are -$5.2 million (Q4 2025), $2.1 million (Q3 2025), and $2.9 million (Q2 2025).